BetterLife Pharma Inc.
BetterLife Pharma Inc. is a Vancouver-based biotechnology company developing pharmaceutical candidates for neurological and neuropsychiatric disorders. Its lead program, BETR-001, is a non-hallucinogenic, non-controlled LSD derivative in preclinical and IND-enabling development, while the company also owns a viral-infection drug candidate and operates through Canadian, Australian, and Hong Kong subsidiaries.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueA non-hallucinogenic LSD derivative being developed for neurological and neuropsychiatric disorders.
A drug candidate owned by BetterLife for potential treatment of viral infections.
Patents and development capabilities supporting compound synthesis, composition, and therapeutic uses.
Customers
BetterLife is primarily a development-stage pharmaceutical company, so its immediate commercial counterparties are expected to be research collaborators, licensing partners, strategic investors, and potential pharmaceutical acquirers rather than a broad base of end patients. Future customers could include healthcare providers, distributors, and patients if BETR-001 or another candidate reaches approval and commercialization. The company’s value proposition to partners is centered on differentiated neurological drug candidates and associated intellectual property.
May license or acquire BETR-001 to access its neurological indications and related patent rights.
Support preclinical, IND-enabling, regulatory, and clinical development activities.
Provide capital to fund drug development in exchange for equity or convertible securities.
Potential future channels for approved neurological or antiviral medicines.
Potential end users of approved therapies for neurological or viral conditions.
Strategy
BetterLife’s strategy centers on advancing BETR-001 through preclinical and IND-enabling studies for neurological and neuropsychiatric indications. The company seeks to use BETR-001’s non-hallucinogenic profile and intellectual property position to address development and regulatory considerations associated with psychedelic-derived medicines. It is also evaluating strategic alternatives for its viral-infection candidate while relying on equity or debenture financing to fund operations and development.
Progress toward regulatory readiness is needed to validate the lead asset and attract partners.
Patent protection can support licensing, partnering, and future commercialization economics.
A strategic transaction or partner could monetize an asset outside the core neurological focus.
Clinical and regulatory programs require capital before product revenue is available.
Geography
BetterLife is headquartered in Vancouver, British Columbia, Canada, and its consolidated structure includes Canadian subsidiaries as well as operations through Altum Pharma in Australia and Altum Pharmaceuticals in Hong Kong. The available reports do not disclose country-level revenue, and the company’s geographic exposure currently reflects research, corporate, and subsidiary activities rather than an established commercial sales footprint.
Risks
BetterLife remains dependent on external financing while its lead candidate is preclinical, creating substantial execution and going-concern risk before any commercial product revenue. BETR-001 may fail in development, face regulatory or patent challenges, or prove difficult to commercialize, while the company also has exposure to dilution and debt-conversion activity. The broader biotech model adds trial, manufacturing, partner-dependence, competitive, and reimbursement risks.
Management states that additional equity or debenture financing may not be available on acceptable terms or on time.
Exposure: Ability to continue operations and fund drug development
BETR-001 is still in preclinical and IND-enabling studies, so safety or efficacy remains unproven.
Exposure: Lead asset valuation and future partnering prospects
Non-hallucinogenic and non-controlled characteristics do not eliminate requirements for regulatory review and clinical evidence.
Exposure: Development timelines and commercialization
Debt conversions and future equity financing increase the share count and may reduce existing ownership percentages.
Exposure: Per-share value and control
Patent claims may be challenged, circumvented, or insufficient to prevent competing neurological therapies.
Exposure: Exclusivity and licensing economics
The company may need strategic partners for development, manufacturing, regulatory execution, and market access.
Exposure: Viral candidate and future BETR-001 commercialization
Accounting
Judgemental itemsManagement identifies substantial doubt because future financing may not be available on acceptable terms.
Impact: Potential material adjustments to assets and liabilities if the company cannot continue operations.
MedMelior is 91% owned and its subsidiaries are consolidated, requiring recognition of outside shareholders’ interests.
Impact: Reported assets, liabilities, revenue, expenses, equity, and net loss include consolidated subsidiary activity.
Preclinical drug programs depend on uncertain technical and regulatory outcomes.
Impact: Failed programs could require impairment or write-offs of capitalized development-related assets.
Principal and accrued interest have been converted into shares and warrants.
Impact: Conversions affect liabilities, equity, finance costs, warrants, and diluted share calculations.
The company granted stock options to officers with multi-year vesting.
Impact: Option grants can increase operating expenses and future diluted shares.
Similar listed companies
Publicly listed companies with a comparable business focus.
Bright Minds Biosciences Inc
DRUG · Pharmaceutical Preparations
XTL Biopharmaceuticals Ltd
XTLB · Pharmaceutical Preparations
Clearmind Medicine Inc.
CMND · Pharmaceutical Preparations
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Relmada Therapeutics, Inc
RLMD · Pharmaceutical Preparations
BioVie Inc
BIVI · Pharmaceutical Preparations
Last updated: 08/09/2026